Paul A. Friedman, M.D., has been a director of Alexion since September 2017. Dr. Friedman served as President and Chief Executive Officer of Incyte Corporation, a leading, publicly traded biopharmaceuticals company, from 2001-2014, where he led a transformation of the business from genomics to a therapeutic focus establishing its foundation as a leader in oncology. Currently, Dr. Friedman serves as Chairman and Chief Executive Officer of Madrigal Pharmaceuticals, Inc., following its merger with Synta Pharmaceuticals Corporation in July 2016. He has also held executive and R&D positions with DuPont Pharmaceuticals Research Laboratories, Merck Research Laboratories, and Merck Sharp & Dohme Corporation.

Dr. Friedman currently sits on the Board of Directors of Incyte Corporation and Madrigal Pharmaceuticals, Inc., both of which are publicly traded biotechnology companies. He previously served on the Board of Directors of Cerulean Pharma, Inc. and Verastem, Inc., both of which were publicly traded companies during Dr. Friedman's service.

Dr. Friedman received his M.D. from Harvard Medical School and his B.S. in Biology from Princeton University.

Dr. Friedman is a member of the Nominating and Corporate Governance Committee and the Science and Innovation Committee.